Using a combination of Selumetinib and Crizotinib, the authors effectively inhibited the growth of ros1 fusion positive cells in vitro and in vivo (Sato et al., 2020), providing a therapeutic strategy for NSCLC. Here, ROS1 is linked to non-small cell lung carcinoma.